thrombocytopenia in chronic hepatitis C
Infectious disease · 2013–2013
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| eltrombopag Treatment of thrombocytopenia in adult patients with chronic hepatitis C virus (HCV) infection to enable initiation and maintenance of interferon-based… | Jul 2013 | Recommended with restriction | no section in document |
What the PBS pays
$27M in government benefit over 2024–25, across 11,807 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| eltrombopag | $27M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.